Anti-HEV – IgG Enzyme Immunoassay (EIA)<<Return to Search Results
Accredited by the Standards Council of Canada to Laboratory no. 594 (ISO/IEC 17025)
Detection of IgG antibody to the Hepatitis E virus by enzyme immunoassay (EIA).
- Hepatitis E
Serum or plasma sample. Minimum volume required for serum or plasma – 0.5 mL.
Collect blood in serum separator tubes (SST) or EDTA tubes.
Store samples refrigerated or frozen until shipped for testing. Ship frozen on wet or dry ice.
Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.
Suspected Hepatitis E infection.
Completed Viral Hepatitis and Bloodborne Pathogens requisition including sender name, address and telephone number. Patient name or identifier (referring specimen lab #), date of birth, suspected exposure, test(s) requested. Type of specimen and date collected. If possible, include the clinical history and lab results that have already been done at local or provincial laboratories.
Microplate EIA, commercially available assay ((Wantai, Beijing Biological Pharmacy Enterprise Co., Ltd.), research use only (RUO)). A positive anti-HEV result may be indicative of current or past infection. A laboratory confirmed case of acute HEV infection requires a combination of anti-HEV IgG and IgM. A single anti-HEV (+) result is more likely to be due to past infection. Very rarely, some patients with anti-HEV IgG but no anti-HEV IgM are viremic (HEV RNA positive by PCR) and satisfy the laboratory criteria for acute case.
15 calendar days.Borderline samples that need to be repeated have an extended turnaround time of 21 calendar days. Urgent clinical specimens require contact with the laboratory prior to submission and have a turnaround time of 3 calendar days.
- Capai L, Falchi A, Charrel R. Meta-Analysis of Human IgG anti-HEV Seroprevalence in Industrialized Countries and a Review of Literature. Viruses. 2019 Jan 20;11(1):84.
- Kodani M, Kamili NA, Tejada-Strop A, Poe A, Denniston MM, Drobeniuc J, Kamili S. Variability in the performance characteristics of IgG anti-HEV assays and its impact on reliability of seroprevalence rates of hepatitis E. J Med Virol. 2017 Jun;89(6):1055-1061.